CANNABIS USE DISORDER

SCF-RDOS INDICATION REGISTRY ENTRY

Classification

DEFINITION

CANNABIS USE DISORDER (CUD) is a substance-use disorder characterized by persistent cannabis consumption despite significant impairment, distress, or adverse consequences affecting cognitive, emotional, behavioral, social, educational, occupational, or physical functioning.

The disorder develops through progressive neuroadaptations within endocannabinoid, dopaminergic, reward-processing, motivational, executive-control, and stress-response systems, resulting in impaired self-regulation, craving, compulsive use patterns, tolerance, withdrawal symptoms, and functional decline.

Within the SCF-RDOS framework, Cannabis Use Disorder is conceptualized as a chronic neurobehavioral dysregulation syndrome involving maladaptive interactions among reward circuitry, executive-control networks, emotional-regulation systems, motivational pathways, and neuroadaptive endocannabinoid signaling mechanisms.

ETIOPATHOGENIC CORE

Primary Pathogenic Theme

Progressive neurobehavioral adaptation to chronic cannabinoid exposure resulting in impaired reward regulation, executive control dysfunction, motivational dysregulation, and compulsive substance-seeking behaviors.

Core Pathogenic Drivers

SCF FAULT ARCHITECTURE

Tier 1 — Foundational Vulnerability Layer

Predisposing Factors

Potential contributors include:

• Family history of substance-use disorders
• Genetic addiction susceptibility
• Childhood adversity
• Trauma exposure
• Impulsivity traits
• Sensation-seeking tendencies
• Emotional dysregulation
• Neurodevelopmental vulnerabilities

Developmental Risk Factors

• Early adolescent cannabis exposure
• Peer substance-use environments
• Poor behavioral supervision
• Social normalization of substance use

Tier 2 — Endocannabinoid and Reward-System Adaptation

Endocannabinoid Dysregulation

Chronic exposure may result in:

• CB1 receptor downregulation
• Altered endocannabinoid signaling
• Neuroadaptive tolerance development
• Reduced endogenous reward responsiveness

Reward-System Remodeling

Potential consequences:

• Altered dopamine signaling
• Reduced natural reward sensitivity
• Reinforcement of cannabis-seeking behavior
• Increased craving vulnerability

Tier 3 — Cognitive and Behavioral Dyscontrol

Executive Function Impairment

Manifestations may include:

• Reduced impulse control
• Poor decision-making
• Impaired planning
• Reduced cognitive flexibility
• Behavioral disinhibition

Motivational Dysregulation

Potential manifestations:

• Reduced goal-directed behavior
• Diminished initiative
• Academic underperformance
• Occupational inefficiency
• Substance-centered prioritization

Withdrawal-Reinforcement Cycle

1. Cannabis reduction or cessation
2. Withdrawal symptoms emerge
3. Emotional discomfort increases
4. Craving intensifies
5. Cannabis use resumes
6. Temporary relief occurs
7. Dependence cycle strengthens

Tier 4 — Functional Dependence and Impairment

Potential outcomes include:

• Academic dysfunction
• Occupational impairment
• Relationship conflict
• Financial burden
• Emotional instability
• Reduced life satisfaction
• Increased psychiatric vulnerability

MOLECULAR MULTI-OMICS PATHOGENESIS MAP

Genomics

Potentially implicated systems:

• Endocannabinoid signaling genes
• Dopaminergic regulation pathways
• Reward-processing susceptibility genes
• Impulsivity-associated polymorphisms
• Stress-response genes

Epigenomics

Potential alterations:

• Substance-induced methylation changes
• Reward-system remodeling signatures
• Stress-related adaptive modifications
• Neurodevelopmental epigenetic alterations

Transcriptomics

Potential dysregulated pathways:

• Endocannabinoid signaling networks
• Reward-processing pathways
• Synaptic plasticity systems
• Addiction-associated neuroadaptive circuits

Proteomics

Potential abnormalities:

• CB1 receptor regulatory proteins
• Dopaminergic signaling proteins
• Neuroplasticity mediators
• Stress-response proteins

Metabolomics

Potential disturbances:

• Endocannabinoid metabolism
• Dopamine metabolism
• Glutamate signaling
• GABAergic regulation
• Neuroenergetic homeostasis

Interactomics

Potential network dysfunction:

• Reward-control imbalance
• Executive-limbic dysconnectivity
• Stress-reward coupling abnormalities
• Motivational network disruption

Connectomics

Frequently implicated neural circuits:

Adapted from SCF multi-omic pathophysiology reconstruction principles.

PATHOGENESIS FLOW (SCF LOGIC)

Genetic and Environmental Vulnerability

↓

Cannabis Exposure

↓

Endocannabinoid Adaptation

↓

Reward-System Remodeling

↓

Tolerance Development

↓

Executive-Control Impairment

↓

Craving and Reinforcement

↓

Compulsive Use Behaviors

↓

Withdrawal-Reinforcement Cycle

↓

Cannabis Dependence

↓

Functional Impairment

CLINICAL PRESENTATION

Behavioral Symptoms

• Compulsive cannabis use
• Repeated unsuccessful cessation attempts
• Excessive time devoted to obtaining or using cannabis
• Continued use despite adverse consequences
• Neglect of responsibilities
• Social withdrawal from non-use activities

Cognitive Symptoms

• Impaired concentration
• Reduced attention
• Executive dysfunction
• Decision-making impairment
• Working-memory difficulties

Emotional Symptoms

• Irritability
• Anxiety
• Emotional lability
• Reduced motivation
• Mood instability
• Emotional dependence on cannabis use

Physiological Symptoms

Tolerance

• Requirement for increased cannabis exposure
• Reduced response to previous doses

Withdrawal Symptoms

May include:

• Irritability
• Anxiety
• Restlessness
• Sleep disturbances
• Reduced appetite
• Dysphoria
• Craving

PATHOGENS → SYMPTOMATOLOGY → SCF FAULT TIER MAPPING

ASSOCIATED CONDITIONS

Cannabis Use Disorder commonly co-occurs with:

• Major Depressive Disorder
• Generalized Anxiety Disorder
• Social Anxiety Disorder
• Attention-Deficit/Hyperactivity Disorder
• Post-Traumatic Stress Disorder
• Bipolar Disorders
• Substance Use Disorders
• Nicotine Dependence
• Psychotic Disorders
• Cannabis-Induced Psychotic Disorder

DIAGNOSTIC CONSIDERATIONS

Core Diagnostic Features

Individuals commonly demonstrate:

• Impaired control over cannabis use
• Persistent use despite harm
• Craving
• Tolerance
• Withdrawal symptoms
• Functional impairment
• Significant time devoted to use behaviors

Differential Considerations

SCF THERAPEUTIC MECHANISMS

SCF-PCR PREVENTATIVE

Objectives

• Delay initiation of cannabis exposure
• Reduce adolescent vulnerability
• Strengthen executive-control development
• Enhance resilience to substance use
• Address environmental risk factors

SCF-PCR CURATIVE

Therapeutic Targets

Endocannabinoid Layer

• Receptor-system normalization
• Neuroadaptive recovery

Reward-System Layer

• Restoration of natural reward sensitivity
• Craving reduction

Executive-Control Layer

• Behavioral self-regulation enhancement
• Decision-making restoration

Emotional-Regulation Layer

• Anxiety management
• Stress-response stabilization
• Adaptive coping development

SCF-PCR RESTORATIVE

Functional Restoration Goals

• Sustained remission
• Academic recovery
• Occupational rehabilitation
• Relationship restoration
• Emotional resilience
• Long-term behavioral self-regulation

CURRENT EVIDENCE-BASED TREATMENT APPROACHES

Psychotherapeutic Interventions

First-Line Approaches

• Cognitive Behavioral Therapy (CBT)
• Motivational Enhancement Therapy (MET)
• Motivational Interviewing (MI)
• Contingency Management
• Relapse Prevention Therapy
• Family-Based Interventions

Therapeutic Objectives

• Increase treatment engagement
• Reduce cannabis use
• Improve coping strategies
• Strengthen relapse resistance
• Enhance behavioral control

Pharmacologic Considerations

Currently, no medication has broad regulatory approval specifically for Cannabis Use Disorder.

Pharmacologic management may focus on:

• Withdrawal symptom management
• Comorbid psychiatric conditions
• Sleep disturbances
• Anxiety symptoms

Treatment should be individualized according to symptom profile and clinical needs.

PROGNOSIS

Prognosis is influenced by:

• Age of onset
• Duration of cannabis exposure
• Severity of dependence
• Psychiatric comorbidity
• Treatment engagement
• Social support
• Cognitive reserve
• Environmental risk factors

Many individuals achieve substantial recovery with structured behavioral treatment and sustained abstinence or significant reduction in use.

PROJECT RHENOVA — INTEGRATION PATHWAYS

Research Axis 1

Multi-omic characterization of endocannabinoid neuroadaptation.

Research Axis 2

Reward-system remodeling and recovery biomarker discovery.

Research Axis 3

Executive-control network connectomics in cannabis dependence.

Research Axis 4

Neurodevelopmental effects of adolescent cannabis exposure.

Research Axis 5

Precision addiction-recovery frameworks using SCF neurobehavioral reconstruction models.

NEXT STRATEGIC RESEARCH PATHWAYS

1. Endocannabinoid recovery biomarker discovery.
2. Cannabis dependence connectomics research.
3. Neurodevelopmental vulnerability mapping.
4. Longitudinal neurocognitive recovery studies.
5. Reward-system restoration investigations.
6. Digital phenotyping of craving and relapse trajectories.
7. AI-assisted relapse prediction systems.
8. Precision treatment-response biomarker development.
9. Neuroplasticity mechanisms of addiction recovery.
10. Functional recovery endpoint development for cannabis-related disorders.

This entry applies SCF pathophysiology, multi-omics integration, addiction-neurobiology modeling, neurobehavioral reconstruction, and therapeutic restoration principles consistent with the SCF-RDOS framework.